- Normal cells need precise control over growth, division, differentiation, survival, and responses to their surrounding environment. A large group of genes participates in this regulation by producing proteins that transmit growth signals, regulate gene expression, control the cell cycle, influence metabolism, and help cells respond to extracellular stimuli. Many of these genes are known as proto-oncogenes because, under normal conditions, their products perform essential functions but can contribute to cancer when their activity becomes abnormally increased or deregulated.
- Proto-oncogenes are therefore not inherently cancer-causing genes. They are normal cellular genes that have important physiological roles. Their products can include growth factors, growth-factor receptors, intracellular signaling proteins, protein kinases, transcription factors, and regulators of cell proliferation and survival. In a healthy cell, the activity of these proteins is carefully controlled. Signals are usually generated only when appropriate, transmitted through defined signaling pathways, and eventually terminated. This regulation allows cells to proliferate when needed without producing uncontrolled growth.
- An oncogene develops when a proto-oncogene becomes altered in a way that promotes inappropriate or excessive cellular activity. The resulting gene can produce an oncoprotein, or can cause excessive production or abnormal activation of an otherwise normal protein. Thus, the relationship can be viewed as a progression from a normal proto-oncogene to an activated oncogene and ultimately to an abnormal oncogenic signaling state. The precise molecular mechanism varies considerably between different oncogenes.
- One of the simplest mechanisms is a gain-of-function mutation. A mutation can alter the structure of a protein so that it becomes continuously active or responds abnormally to regulatory signals. RAS proteins provide a classic example. Normal RAS functions as a molecular switch, cycling between an inactive GDP-bound state and an active GTP-bound state. Specific mutations can interfere with the mechanisms that normally terminate RAS signaling, leaving the protein preferentially in its active state. Persistent RAS signaling can then stimulate downstream pathways involved in proliferation and survival.
- Another mechanism is gene amplification, in which multiple copies of a proto-oncogene become present within a cancer cell. Increased gene dosage can lead to increased production of the corresponding protein. If the protein stimulates growth or survival, its excessive abundance can contribute to oncogenic transformation. HER2, which encodes a receptor tyrosine kinase, is a well-known example in which gene amplification can produce abnormally high receptor levels and persistent growth-promoting signaling in certain cancers.
- Proto-oncogenes can also become oncogenic through overexpression. Unlike gene amplification, overexpression does not necessarily require an increase in gene copy number. Changes in regulatory sequences, transcriptional control, RNA stability, protein stability, or other mechanisms can cause excessive production of a normal protein. The distinction is important because oncogenic activity can result not only from a structurally abnormal protein but also from an excessive amount of a normally functioning protein.
- Chromosomal rearrangements represent another major mechanism of oncogene activation. A chromosome can undergo translocation, inversion, deletion, or another structural alteration that changes the genomic context of a proto-oncogene. The rearrangement may place the gene next to a highly active regulatory element, causing excessive expression, or may join portions of two genes together to produce a novel fusion protein. Fusion oncoproteins can possess abnormal enzymatic activity, altered localization, or new protein-protein interactions.
- The BCR-ABL fusion illustrates how a chromosomal rearrangement can generate a powerful oncogenic protein. The Philadelphia chromosome results from a reciprocal translocation involving chromosomes 9 and 22, producing a BCR-ABL fusion gene. Its product is a constitutively active tyrosine kinase that continuously stimulates signaling pathways promoting cell proliferation and survival. This example also demonstrates how understanding the molecular origin of an oncogene can directly contribute to the development of targeted cancer therapy.
- Some oncogenes become activated because a proto-oncogene is placed under the control of an inappropriate enhancer or promoter. This mechanism can produce excessive transcription without changing the protein’s amino-acid sequence. In certain lymphoid malignancies, chromosomal rearrangements can place growth-promoting genes close to highly active immunoglobulin regulatory elements, leading to abnormal expression. In this situation, the oncogenic effect results primarily from deregulated gene expression rather than production of a structurally abnormal protein.
- The biological effects of oncogene activation depend strongly on the type of protein involved. An activated receptor tyrosine kinase can continuously transmit growth signals from the cell membrane. An activated intracellular kinase can stimulate downstream signaling independently of extracellular signals. An altered small GTPase such as RAS can maintain intracellular signaling in an active state. An overexpressed transcription factor such as MYC can alter the expression of large groups of genes involved in growth and metabolism. Although these proteins operate at different levels of cellular regulation, they can ultimately produce overlapping phenotypes such as increased proliferation and enhanced survival.
- The distinction between proto-oncogenes and oncogenes is therefore closely related to the concept of regulated signaling versus deregulated signaling. A normal proto-oncogene product is generally activated only when appropriate and is subsequently switched off. An oncogenic alteration can remove one or more of these regulatory constraints. The resulting protein may remain active, become excessively abundant, appear in an abnormal cellular location, interact with inappropriate partners, or acquire a new biochemical function.
- Oncogene activation alone does not necessarily mean that a normal cell immediately becomes a fully malignant tumor. Cancer development usually involves the accumulation of multiple genetic and epigenetic alterations. An activated oncogene can provide one important growth or survival advantage, but additional changes affecting tumor suppressors, DNA-damage responses, cell-cycle checkpoints, apoptosis, genome stability, and the tumor microenvironment can contribute to subsequent tumor development.
- This cooperation between oncogenic and tumor-suppressive alterations is particularly important in understanding cancer progression. An activated oncogene may stimulate proliferation, while loss of a tumor suppressor can remove mechanisms that would normally stop the abnormal cell or trigger its elimination. The combination can therefore produce a much stronger effect than either alteration alone. Cancer cells can subsequently acquire additional changes through clonal evolution, allowing populations with advantageous characteristics to expand.
- The cellular context also determines how strongly an oncogene influences cancer development. The same oncogenic alteration may produce different effects in different tissues because cells differ in their transcriptional programs, signaling networks, metabolic states, differentiation status, and interactions with neighboring cells. Consequently, an oncogene should not be considered an isolated molecular switch. Its effects emerge from the network of pathways operating within a particular cellular environment.
- Oncogenes can also influence processes beyond proliferation. Activated oncogenic pathways may increase cell survival, alter cellular metabolism, stimulate angiogenesis, modify interactions with the extracellular matrix, promote cellular plasticity, and influence immune responses. These effects help explain why oncoproteins can contribute to several different characteristics of cancer simultaneously.
- The concept of proto-oncogenes also provides an important connection between normal developmental biology and cancer biology. Many proto-oncogene products are essential during embryonic development, tissue regeneration, wound healing, and normal immune-cell activation. Their ability to stimulate proliferation is therefore not inherently abnormal. Cancer can arise when these powerful physiological programs become activated inappropriately, persist for too long, or become disconnected from the regulatory mechanisms that normally restrict them.
- Modern cancer genomics has greatly expanded the number of known oncogenic alterations. Large-scale sequencing studies can identify recurrent mutations, copy-number changes, gene amplifications, and chromosomal rearrangements across different tumor types. These findings help distinguish important driver alterations from mutations that are present in tumors but do not substantially contribute to their growth. Functional experiments are often required to determine whether a particular alteration genuinely produces an oncogenic phenotype.
- The discovery of oncogenes has also transformed cancer treatment. If a tumor depends strongly on an activated oncogene, blocking the corresponding protein or its signaling pathway may selectively impair cancer-cell growth. This principle has led to the development of targeted therapies against proteins such as BCR-ABL, EGFR, HER2, BRAF, ALK, and several other oncogenic drivers. However, cancer cells can evolve resistance through secondary mutations, pathway bypass mechanisms, amplification of alternative signaling components, or changes in cellular state.
- An important concept emerging from this field is oncogene addiction, in which a cancer cell becomes unusually dependent on a particular oncogenic pathway even though the tumor contains many other genetic abnormalities. This dependence can create a therapeutic vulnerability. At the same time, oncogene dependence is not always permanent, and tumors can adapt when the targeted pathway is inhibited.
- The transition from proto-oncogene to oncogene can therefore occur through several fundamentally different mechanisms: mutation can alter protein activity, amplification can increase protein abundance, regulatory changes can cause overexpression, and chromosomal rearrangements can create either abnormal expression patterns or novel fusion proteins. Despite their differences, these mechanisms converge on a common biological consequence: disruption of normal control over cellular signaling and behavior.
